Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapendavir for Rhinovirus in COPD
NCT07610395Phase 2Recruiting
- Sponsor
- Altesa BioSciences
- Start
- May 2026
- Primary completion
- Nov 2027
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Vapendavir in rhinovirus infection (3 arms), sponsored by Altesa BioSciences. Primary endpoint: Evaluating Respiratory Symptoms at 42 days. Started May 2026; status: recruiting.
02
Drugs
Vapendavir
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT07610395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610395.